What Can You Expect at the 5th Viral Vector Process Development & Manufacturing Summit
You're investing significant time and resources into viral vector development, yet challenges around transfection variability, purification losses, and low manufacturing productivity continue to limit clinical progression and commercial viability. The 5th Viral Vector Process Development & Manufacturing Summit is designed to help you overcome these bottlenecks through real-world case studies, practical discussions, and peer-to-peer knowledge sharing from the industry's leading viral vector experts.
At this year's meeting, you will:
- Learn how leading developers are optimizing transfection strategies across triple transfection, packaging cell lines, and producer cell lines to improve yields, consistency, and manufacturing robustness
- Explore advanced purification and capsid separation approaches to increase potent product recovery, reduce impurities, and maximize manufacturing efficiency
- Discover proven strategies for improving process productivity and speed to reduce cost of goods, accelerate clinical progression, and support sustainable commercialization
Event Highlights
Accelerate Clinical & Commercial Readiness Through Platform Manufacturing Strategies
Learn how to leverage platform knowledge and prior process experience to reduce development burden, strengthen regulatory confidence, and accelerate PPQ readiness under compressed CMC timelines.
Hear From:
- Pranav Puri, Associate Director BioProcess Development, VectorY Therapeutics
- Jack Ren, Director, Downstream Process Development, Global CMC Development, Ultragenyx
Maximize Potent Product Recovery Without Sacrificing Purity
Explore advanced chromatography and purification strategies that increase potent product recovery, improve purity, and reduce manufacturing losses. Learn how emerging analytical tools are strengthening process optimization and regulatory confidence.
Hear From:
- Mukesh Mayani, Senior Director, Global CMC Development, Ultragenyx
- Jessica Chia-Yun Sun, Senior Director, AAV Downstream Development, Alexion Pharmaceuticals
- Andrew Tustian, Executive Director, Preclinical Manufacturing & Process Development, Regeneron Pharmaceuticals
Build Platform-Ready AAV Manufacturing for Faster Clinical Progression
Discover how leading developers are leveraging platform-ready AAV manufacturing, engineered capsids, and FDA platform designation strategies to increase productivity, reduce development burden, and accelerate programs from first-in-human studies to commercialization.
Hear From:
- Jorge Santiago-Ortiz, Vice President, CMC & Regulatory Affairs, Apertura Gene Therapy
- Wenbin Qi, Associate Director, Neurocrine Biosciences
- Matt Edwards, Vice President Technical Operations, Affinia Therapeutics
- Michael White, CMC Lead, Celosia Therapeutics
Explore the Full Event Guide
- Explore proven strategies to increase yields and reduce manufacturing costs
- Benchmark platform manufacturing approaches accelerating clinical and commercial success
- Discover practical solutions for transfection, purification, and process scalability
- Learn how leading developers are improving robustness, reproducibility, and regulatory readiness
- Preview insights from experts at Ultragenyx, Regeneron, Legend Biotech, Alexion, Sanofi, and more
Attending Companies Include
Explore the Agenda
Discover proven strategies for increasing yields, reducing manufacturing costs, and building scalable viral vector platforms.
Partner With Us
Connect directly with the viral vector leaders seeking technologies, services, and partners to accelerate manufacturing success.
Join Viral Vector Leaders
Benchmark approaches with senior CMC, process development, manufacturing, MSAT, and regulatory experts advancing viral vector-based therapies.